Year All2024202320222021 KemPharm to Report First Quarter 2022 Financial Results 05-04-2022 KemPharm Doses First Subject in Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX) 04-19-2022 KemPharm Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Corporate Updates 03-30-2022 KemPharm to Participate in Maxim’s 2022 Virtual Growth Conference 03-24-2022 KemPharm Announces Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial 03-21-2022 KemPharm Earns $1.975 Million Fee from Corium Following FDA Approval of the Corium Product ADLARITY® (donepezil transdermal system) 03-16-2022 KemPharm to Report Fourth Quarter and Full-Year 2021 Results 03-10-2022 KemPharm Completes KP1077 Pre-IND Meeting Process with FDA 02-23-2022 KemPharm Issues Letter to Shareholders Detailing Strategic Focus on CNS/Rare Disease Indications and Updated Clinical Development Strategy 01-19-2022 KemPharm to Host Investor Conference Call Detailing Plans for Pipeline Expansion 01-12-2022
KemPharm Doses First Subject in Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX) 04-19-2022
KemPharm Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Corporate Updates 03-30-2022
KemPharm Announces Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial 03-21-2022
KemPharm Earns $1.975 Million Fee from Corium Following FDA Approval of the Corium Product ADLARITY® (donepezil transdermal system) 03-16-2022
KemPharm Issues Letter to Shareholders Detailing Strategic Focus on CNS/Rare Disease Indications and Updated Clinical Development Strategy 01-19-2022
